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Abstract
Objective: Subclinical joint inflammation in patients with arthralgia is predictive for progression to rheumatoid
arthritis (RA). However, the time course of progression for bone marrow edema (osteitis), synovitis, and/or
tenosynovitis is unsettled. This longitudinal study assessed the course of magnetic resonance imaging (MRI)-
detected subclinical joint inflammation during progression to RA.
Methods: Patients that progressed from clinically suspect arthralgia (CSA) to RA underwent 1.5-T MRI of the
metacarpophalangeal (MCP), wrist, and metatarsophalangeal (MTP) joints at presentation with arthralgia and at
first identification of synovitis assessed through physical examination (n = 31). MRIs were evaluated for osteitis,
synovitis, tenosynovitis, and erosions by two readers, blinded for clinical data and order in time. To estimate
changes in MRI scores between the asymptomatic state and CSA onset, scores of MRI features at CSA baseline were
compared with scores from age-matched symptom-free persons.
Results: At presentation with CSA, synovitis and tenosynovitis scores were higher than scores from age-matched
symptom-free persons (p = 0.004 and p = 0.001, respectively). Anti-citrullinated protein antibody (ACPA)-positive
arthralgia patients also had increased osteitis scores (p = 0.04). Median duration between presentation with arthralgia
and RA development was 17 weeks. During progression to RA, synovitis and osteitis increased significantly (p = 0.001
and p = 0.036, respectively) in contrast to tenosynovitis and erosion scores. This pattern was similar in both ACPA
subsets, although statistical significance was reached for synovitis and osteitis in ACPA-negative but not
ACPA-positive RA.
Conclusion: Increased tenosynovitis and synovitis scores at CSA onset and the increase in synovitis and osteitis during
progression to RA suggest an ‘outside-in’ temporal relationship of arthritis development, in particular for ACPA-negative
RA. For ACPA-positive RA, further studies are needed.
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Background
Rheumatoid arthritis (RA) can be diagnosed at the time
patients present with clinically detectable inflammatory
arthritis (swollen joints). It is known that immunological
alterations are present long before that [1]. For instance,
magnetic resonance imaging (MRI)-detected subclinical
inflammation is present weeks to months before arthritis
becomes clinically apparent in patients presenting with
clinically suspect arthralgia (CSA) and has been shown
to be predictive for RA development [2]. Nonetheless, a
long-standing question is where inflammation starts in
the joint, or in what order the different tissues of the
joints (synovium, tenosynovium, and bone) become in-
flamed during the development of RA.
Several hypotheses on the chronology of arthritis devel-
opment prevail. Firstly, it has been postulated that synovitis
is an initial process that is succeeded by bone involvement.
This is the traditional ‘outside-in hypothesis’, presuming
that inflammation of the synovium precedes bone marrow
edema (or osteitis) [3–7]. Alternatively, it has been sug-
gested that RA is a primary bone marrow disease which
subsequently encroaches upon the synovial membrane; this
is the ‘inside-out hypothesis’, with osteitis preceding syno-
vitis, a hypothesis that has become popular after imaging
and histological studies revealed the presence of osteitis at
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locations with MRI-detected osteitis in patients with RA
[4, 7, 8]. It has also been hypothesized that these processes
could emerge and progress simultaneously with micro-
scopic bone canals allowing transduction of inflammation
from the outside (synovium) to the inside (bone marrow)
and vice versa [4, 7, 9]. Finally, mouse models of arthritis
development have shown that tenosynovitis was the initial
preclinical change [10]. Extrapolation to humans would
suggest that tenosynovitis rather than synovitis or osteitis
is the primary feature of joint inflammation [10]. For the
development of bone erosions (instead of the development
of clinically apparent inflammatory arthritis) similar hy-
potheses have been postulated, with the primary inflamma-
tion located inside [11, 12] or outside the bone [13],
respectively. Altogether, temporal relationships are yet un-
known and can be discovered by longitudinal imaging
studies that start in pre-arthritis phases of the disease.
To address the question about the chronological order
in which the different tissues of the joints become in-
flamed, this longitudinal MRI study investigated the
course of MRI-detected subclinical joint inflammation
(synovitis, tenosynovitis, osteitis) and erosions in pa-
tients that presented with arthralgia and progressed to
RA. MRIs were performed longitudinally at presentation
with arthralgia and at development of RA. Although no
MRIs were made in the asymptomatic phase of these pa-
tients, the MRI data obtained at presentation with arth-
ralgia were compared with data obtained in age-matched
symptom-free persons to estimate the course of inflam-
mation before presentation with arthralgia. Finally, as
anti-citrullinated protein antibody (ACPA)-positive and
ACPA-negative RA are considered as different disease
subsets with differences in the underlying pathophysi-
ology, analyses were stratified for ACPA-positive and
ACPA-negative RA to explore if there are differences in
the chronological order in which different articular tis-
sues become inflamed.
Patients and methods
Patients
We longitudinally followed patients that presented with
CSA between April 2012 and September 2016. The Lei-
den CSA cohort consecutively included patients that
presented at the rheumatology outpatient clinic of the
Leiden University Medical Centre without clinically evi-
dent arthritis, but with recent-onset (< 1 year) arthralgia
of small joints that was considered at risk for RA by
their rheumatologists based on the clinical presentation
[14]. A detailed description of the inclusion and exclu-
sion criteria of the Leiden CSA cohort and the study
protocol are described in [15]. Absence of clinical arth-
ritis at baseline was ascertained through physical exam-
ination by an experienced rheumatologist.
Regular follow-up visits in the cohort were planned at 4,
12, and 24 months. If necessary (for instance, when the
patient experienced more symptoms or noticed a swollen
joint), patients were seen in between scheduled visits by
their rheumatologist. Hence, logistics were arranged such
that patients in this cohort had very easy access to
rheumatology care, and clinically evident inflammatory
arthritis was identified at the first opportunity. The out-
come was clinically apparent arthritis, identified at joint
examination by an experienced rheumatologist. Previous
studies revealed that ~ 20% of patients that presented with
CSA progressed to clinically apparent inflammatory arth-
ritis [2].
For this study we selected the patients included in the
CSA cohort that developed clinically apparent RA. A
flowchart is provided in Fig. 1. From a total of 416 pa-
tients included in the CSA cohort during the studied
period, 76 were diagnosed with RA. Serial MRI was per-
formed at baseline and at arthritis development (but be-
fore disease-modifying antirheumatic drugs (DMARDs)
were started). Of the 76 RA patients, serial MRIs were
available in 35 patients. In 41 patients serial imaging was
not available because four patients had contraindications
for gadolinium contrast, three patients progressed to RA
in a very short period of time, and 34 patients were lack-
ing serial MRI due to logistical reasons.
Thirty-five patients were diagnosed with RA and had
serial MRI available. Four out of these 35 patients did
not receive a prescription for a DMARD at the visit
when clinical arthritis was identified (three patients sub-
sequently had resolution of arthritis, one patient re-
ceived a prescription at the next visit). Thus, in total 31
patients with a clinical diagnosis of RA and immediate
prescription of DMARDs were studied. Notably, fulfil-
ment of the 2010 classification criteria was not required
to define RA since ACPA-negative patients require > 10
involved joints to fulfil these criteria [16] and this can be
hampered by DMARD initiation. Nonetheless, despite
this theoretical threshold, 21 patients (68%) fulfilled the
2010 criteria for RA at arthritis development. It is im-
portant to note that DMARDs (including corticoste-
roids) were not prescribed in the phase of arthralgia.
Symptom-free persons
Serial MRIs were not made in the period preceding pres-
entation with CSA. To infer the course of MRI-detected
subclinical inflammation over time before the phase of
CSA, the MRI data from the 31 CSA patients were com-
pared with data from symptom-free persons [17].
Symptom-free persons were matched based on age in a
1:2 ratio. These 62 symptom-free persons had no history
of inflammatory rheumatic diseases, no joint symptoms
during the previous month, and no evidence of synovitis
at physical examination. The persons were retrieved from
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the general population; the recruitment procedure is de-
scribed elsewhere [17]. Since gender (p = 0.10), increased
body mass index (BMI) (p = 0.59) [18], and smoking (p =
0.21) had no effect on MRI-detected inflammation,
matching was not performed on these factors.
MRI
Unilateral MRIs of the wrist, metacarpophalangeal
(MCP) joints 2–5, and metatarsophalangeal (MTP) joints
1–5 were performed at presentation with CSA (on the
most painful side) and at first presentation with clinical
synovitis (the same side as scanned at baseline). A total of
18 tenosynovitis locations were scored in each patient: 10
at the wrist, including 6 extensor compartments and 4 re-
gions on the volar side (the flexor digitorum profundus
and flexor digitorum superficialis, the flexor pollicis
longus, the flexor carpi ulnaris, and the flexor carpi radia-
lis), and 8 locations at MCP joints 2–5 (paired flexor ten-
dons and extensor tendons of the fingers). An ONI MSK
Extreme 1.5-T MRI scanner (GE Healthcare, Wisconsin,
USA) was used as described previously [2] and in
Additional file 1 (Supplementary methods). All patients
were instructed not to use nonsteroidal anti-inflammatory
drugs (NSAIDs) 24 h prior to MRI, with only seven pa-
tients (23%) reporting the daily use of NSAIDs at baseline.
The serial MRIs were scored blinded for clinical data and
order in time by two readers for osteitis, erosions,
and synovitis as described in [19] and tenosynovitis as
described in [20]. The mean scores of two readers
were studied. Additional information on the scoring is
provided in Additional file 1 (Supplementary methods).
Three readers contributed to the scoring of the MRIs.
Within-reader intraclass correlation coefficients (ICCs)
and between-reader ICCs were all > 0.90 and are also pre-
sented in Additional file 1 (Table S1). Results of MRI were
not shared with the treating rheumatologists.
Analyses
Paired t tests were used. Longitudinal modeling was per-
formed using generalized estimating equations (GEE);
the scores of the different inflammatory features and
erosions were studied over time. The GEE models, utiliz-
ing an unstructured correlation matrix, corrected for the
influence of age, gender, and time to progression to RA
and baseline score per feature. Residuals of GEE model-
ing were checked for normal distribution. Statistical ana-
lyses were performed using the Statistical Package for
the Social Sciences (SPSS, version 23.0). P values < 0.05
were considered significant.
Results
Patients
Characteristics of the 31 RA patients studied were similar
to the total group of 76 patients diagnosed with RA, except
for a lower frequency of ACPA positivity in the studied
group (Additional file 1: Table S2). Baseline characteristics
of the 31 patients studied are presented in Table 1. The
mean age was 44 years, 71% were female, the median ten-
der joint count (68-TJC) was 5 (interquartile range (IQR)
4–10), 42% were rheumatoid factor-positive, and 29% were
Fig. 1 Flowchart of selection of rheumatoid arthritis (RA) patients studied from the total CSA cohort. Patient characteristics of the different groups
are provided in Additional file 1 (Table S2). DMARD disease-modifying antirheumatic drug, MR magnetic resonance, MRI magnetic
resonance imaging
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ACPA-positive. These characteristics are in line with previ-
ous research in CSA patients [15]. The median interval be-
tween presentation with arthralgia and progression to RA
was 17 weeks. The characteristics of the 31 patients at the
time of identification of RA are also presented in Table 1.
The DMARDs that were initiated after RA development
are presented in Additional file 1 (Table S3).
MRI data at presentation with arthralgia compared with
that of age-matched symptom-free controls
Compared with age-matched symptom-free persons from
the general population, CSA patients had increased teno-
synovitis (mean 1.7 versus 0.27; p < 0.001) and synovitis
scores (2.2 versus 0.93; p < 0.001; Fig. 2). Osteitis scores
(1.9 versus 1.4; p = 0.35) and erosion scores (1.7 versus 1.8;
p = 0.53) were not significantly elevated (Fig. 2) at presen-
tation with arthralgia.
Inflammation increased during progression from
arthralgia to rheumatoid arthritis
During progression from arthralgia to RA, the mean os-
teitis score increased from 1.9 to 2.7 (p = 0.036), and the
mean synovitis score from 2.2 to 3.4 (p = 0.001; Fig. 2).
Tenosynovitis and erosion scores did not increase sig-
nificantly (mean 1.7 to 2.0, p = 0.35, and 1.7 to 1.9, p =
0.092, respectively; Fig. 2). Next, GEE models were con-
structed, allowing longitudinal data comparisons of MRI
inflammatory scores. These models corrected for gender,
age at inclusion, time interval to RA, and the score of
each feature (e.g., osteitis) at presentation with CSA.
GEE modeling demonstrated that only synovitis scores
(β = 1.0; p = 0.004) were significantly higher at the time
of RA development than at presentation with arthralgia.
Stratification for ACPA status
Finally, we explored if results were different in
ACPA-positive and ACPA-negative RA patients, although
absolute numbers were small (n = 9 and n = 22, res-
pectively). ACPA-positive patients had higher osteitis scores
(p = 0.04), synovitis scores (p < 0.001), and tenosynovitis
scores (p < 0.001) at presentation with arthralgia compared
with age-matched symptom-free persons. ACPA-negative
patients had higher synovitis scores (p = 0.02) and teno-
synovitis scores (p = 0.001), but the osteitis score was not
different (p = 0.24). Erosion scores were not different from
age-matched symptom-free persons in both ACPA-positive
and ACPA-negative patients at presentation with arthralgia.
Over time, during progression from arthralgia to RA,
ACPA status did not change for any of the patients. In
ACPA-negative patients, osteitis and synovitis score in-
creased significantly (1.1 to 1.7, p = 0.03, and 1.8 to 2.9, p
= 0.003, respectively) during progression from arthralgia
to RA, whereas tenosynovitis and erosion scores remained
stable (Fig. 3). In ACPA-positive patients, no statistical sig-
nificance was obtained but osteitis scores increased from
3.6 to 5.2 (p = 0.22) and synovitis from 3.1 to 4.5 (p =
0.13). Tenosynovitis scores were 1.7 and 2.3 (p = 0.32) and
erosion scores were 2.4 and 2.6 at presentation with arth-
ralgia and RA, respectively (p = 0.62; Fig. 3).
Finally, analyses were repeated for autoantibody-positive
(positive for either rheumatoid factor and/or ACPA; n = 16)
and autoantibody-negative patients (n = 15). Similar results
were obtained as for ACPA-positive and ACPA-negative
RA patients as described above (data not shown).
Discussion
To increase our understanding of the chronological
order of joint inflammation during the development of
RA, serial MRIs were made in RA patients at the time of
Table 1 Characteristics of the RA patients at presentation with clinically suspect arthralgia and at first identification of clinical
arthritis and age-matched symptom-free volunteers
At presentation with
arthralgia (n = 31)
At presentation
with RA (n = 31)
Age-matched symptom-free
volunteers (n = 62)
Age (years), mean (SD) 44 (14) – 44 (13)
Female sex, n (%) 22 (71) – 38 (61)
Symptom duration (weeks), median (IQR) 17 (9–32) – n/a
Presence of morning stiffness ≥ 60 min, n (%) 11 (35) 24 (77) 0 (0)
68-TJC, median (IQR) 5 (4–10) 7 (5–12) 0 (0–0)
66-SJC, median (IQR) 0 (0–0) 2 (1–5) 0 (0–0)
Increased CRP (≥ 5 mg/L), n (%) 6 (19) 7 (29) n/a
Autoantibody status
IgM-RF-positive (≥ 3.5 IU/mL), n (%) 13 (42) 13 (42) n/a
ACPA-positive (≥ 7 U/mL), n (%) 9 (29) 9 (29) n/a
Any antibody-positive (either RF or ACPA) 16 (52) 16 (52) n/a
ACPA anti-citrullinated peptide antibody, CRP C-reactive protein, IgM-RF immunoglobulin M rheumatoid factor, IQR interquartile range, n/a not applicable or not
assessed, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation, SJC swollen joint count, TJC tender joint count
ten Brinck et al. Arthritis Research & Therapy          (2018) 20:260 Page 4 of 8
Fig. 2 Magnetic resonance imaging (MRI) features of joint inflammation and erosions in patients that developed rheumatoid arthritis (RA). MRI
was performed at presentation with arthralgia and at diagnosis of RA. MRIs were not made in the asymptomatic phase but the course of local
inflammation before presentation with arthralgia was estimated by comparisons with age-matched symptom-free persons (1:2 ratio to patients).
Since these data were not measured longitudinally, data are presented in dashed lines. *p < 0.05. CSA clinically suspect arthralgia
Fig. 3 Magnetic resonance imaging (MRI) features of joint inflammation and erosions in patients that developed rheumatoid arthritis (RA)
stratified for anti-citrullinated protein antibody (ACPA) status. MRI was performed at presentation with arthralgia and at diagnosis of RA. MRIs
were not made in the asymptomatic phase but the course of local inflammation before presentation with arthralgia was estimated by comparisons
with age-matched symptom-free persons (1:2 ratio to patients). Since these data were not measured longitudinally, data are presented in dashed lines.
*p < 0.05 by paired t test. CSA clinically suspect arthralgia
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presentation with arthralgia and at first identification of
RA. This revealed that synovitis and osteitis increased
during the symptomatic pre-arthritis phase. In addition,
data on MRI-detected subclinical inflammation obtained
at presentation with arthralgia were compared with data
from age-matched symptom-free persons. This showed
that synovitis and tenosynovitis scores were higher in
patients with arthralgia, suggesting that these features
had already increased at presentation with arthralgia.
The erosion scores did not increase, neither in the
asymptomatic nor during the symptomatic phase pre-
ceding the identification of RA. Together, these results
suggest that tenosynovitis and synovitis are the earliest
inflammatory features. Subsequently, synovitis and oste-
itis increased over time in the symptomatic pre-arthritis
phase, whereas erosions did not increase before RA had
become apparent. This implies that inflammation mainly
starts outside the bone (fitting the outside-in hypoth-
esis), after which osteitis develops, which puts the joint
at risk for structural damage development in the phase
of clinically evident RA (if left insufficiently treated).
Stratification for ACPA status showed that synovitis and
osteitis progressed similarly during the symptomatic
pre-arthritis phase in both ACPA subsets, but that
ACPA-positive arthralgia patients already had higher oste-
itis scores at presentation with arthralgia. This could be ex-
plained by a longer symptom duration of ACPA-positive
patients at presentation with arthralgia: median symptom
duration at baseline was 22 weeks in ACPA-positive CSA
patients and 15 weeks in ACPA-negative CSA patients
(Additional file 1: Table S3). As established previously,
ACPA-positive RA has a more gradual onset of symptoms
[21]. ACPA-positive patients may therefore have presented
in a slightly later phase of the disease. Alternatively, this
finding could also imply a different chronology of joint in-
flammation in ACPA-negative and ACPA-positive RA, with
osteitis being one of the first inflammatory features in
ACPA-positive RA. This could be in line with the associa-
tions of autoantibody status and osteitis scores observed in
the phase of classifiable RA [22].
There are several limitations to this study. One limita-
tion is that the analyses were performed on the sum of
synovitis, osteitis, and tenosynovitis scores observed in
310 joints, 1023 bones, and 868 tendons. Whilst it would
be interesting to perform similar analyses at the individ-
ual joint/bone/tendon level, this was not done because
of low numbers of joints/bones/tendons with subclinical
inflammation. Larger studies are needed to this end.
Another limitation is the sample size. Although all pa-
tients that developed RA from a total cohort of consecu-
tive CSA patients (with serial MRI available) were
studied, the absolute number (n = 31) is rather small.
Future longitudinal imaging studies are therefore re-
quired to validate the results. Nonetheless, the present
study is the largest longitudinal MRI study in a popula-
tion of patients that converted from arthralgia to RA
that is available to date.
Analyses were stratified for ACPA to explore differences
between these subgroups, although the ACPA-positive
subgroup especially was rather small. This may be ex-
plained by more intramuscular corticosteroid injections in
ACPA-positive patients, preventing the performance of an
MRI before DMARD initiation. Larger future studies, es-
pecially in ACPA-positive convertors, are needed.
Another limitation is that MRIs were made at first pres-
entation with CSA and at development of RA, but no
scans were made in between. Furthermore, patients were
included at first presentation with clinically suspect arth-
ralgia and were not scanned in an asymptomatic phase.
Although some information on the chronology of joint in-
flammation in this disease phase was obtained by com-
parison of data obtained in age-matched symptom-free
persons, this analysis was cross-sectional in nature and
therefore less reliable than longitudinally collected data.
Hence, future longitudinal imaging studies would be still
highly relevant to further increase our understanding of
RA development.
In our study, T1-weighted fat-suppressed sequences
were obtained. These were previously demonstrated to
have a strong correlation with T2-weighted fat-suppressed
sequences in three studies [23–25]. Furthermore, persist-
ent osteitis was strongly associated with erosive progres-
sion using these sequences [11]. Taken together, these
findings demonstrate that osteitis is an established risk
factor for the development of articular bone erosions re-
gardless of the acquired sequence. The lack of a significant
increase in osteitis scores between asymptomatic persons
and arthralgia patients is more likely to be caused by the
(early) disease stage in which the patients were assessed
rather than a difference due to the scanning protocol.
Nevertheless, replication of our results using T2-weighted
fat-suppressed sequences is warranted.
Future serial imaging studies performed in the asymp-
tomatic phase until development of RA would be useful to
further elucidate the chronology in which the different ar-
ticular tissues become inflamed. However, this cannot be
easily accomplished as the 5-year positive predictive value
of ACPA in the general population is approximately 5%
[26, 27]. Consequently, 20 symptom-free ACPA-positive
persons would need to be followed for several years with
serial MRIs to acquire longitudinal data of one RA patient.
Studying 30 ACPA-positive RA patients already in the
asymptomatic phase would require serial imaging in ~ 600
ACPA-positive symptom-free persons during several years
of follow-up. Hence, although challenging, studying tem-
poral relationships of inflammatory features during pro-
gression from the asymptomatic to the symptomatic
pre-arthritis phase is a subject for follow-up research.
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Animal studies have demonstrated that tenosynovitis is
the earliest inflammatory joint feature in murine models
[10]. Studies in CSA patients have also revealed that, of all
three inflammatory features, tenosynovitis is the strongest
predictor for RA development [2]. The current data,
showing that tenosynovitis is a very early phenomenon,
denote the importance of inflammation of synovial tendon
sheaths in very early phases of RA development.
The erosion score did not increase in the pre-arthritis
phase, in contrast with the osteitis score. Previous re-
search has revealed that osteitis that persisted in the
early clinical phase of RA was strongly associated with
erosion development (odds ratio ~ 60) at the same loca-
tion [11]. CSA patients in this study had very early ac-
cess to rheumatologic care in case of symptom
deterioration or if they suspected joint swelling. There-
fore, we expect that patients were seen very shortly after
clinical synovitis had developed. In addition, the median
duration to development of RA was relatively short
(17 weeks). Both factors may explain why articular bone
erosions were not (yet) increased during the studied
period. Based on MRI data collected in early arthritis pa-
tients [11], we anticipate that the bones with osteitis at
RA presentation were at risk for development of ero-
sions, but the time period was too brief for actual ero-
sive progression. This is in line with previous studies
showing that MRI-detected erosions predominantly de-
veloped in joints with persistent osteitis [11].
Imaging using ultrasound (US) can be used to assess
the presence of synovitis and tenosynovitis. Our data,
obtained in the earliest disease phases, could suggest
that US could suffice for assessment of these features.
However, US cannot depict osteitis which may also pro-
vide valuable information. Studies in larger patient
groups are needed before the present findings can be
translated to clinical practice, although the present data
contribute to our understanding of clinical arthritis and
RA development.
Conclusions
In summary, the data provided on RA patients suggest
an increase of tenosynovitis and synovitis scores before
the onset of arthralgia. Our study demonstrated that
synovitis and osteitis scores increased during progression
from arthralgia to clinical arthritis, suggesting an ‘outsi-
de-in’ temporal relationship of arthritis development,
particularly in ACPA-negative RA. For ACPA-positive
RA further studies are needed.
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